A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients

European Journal of Cancer

Volumn 55, Issue , 2016, Pages 81-97

  Bollineni, V R ^a   Kramer, G M ^b   Jansma, E P ^b   Liu, Y ^a   Oyen, W J G ^c  

^a EORTC DATA CENTER   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

3 Deoxy 3 (18F)fluorothymidine; Alovudine; Cell proliferation; Chemoradiotherapy; Chemotherapy; Imaging biomarker; Neoplasms; Postitron emission tomography; Radiotherapy

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; RADIOPHARMACEUTICAL AGENT;

CELL PROLIFERATION; DISEASE FREE SURVIVAL; HUMAN; MORTALITY; NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING; TREATMENT OUTCOME;

CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84955239068     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.018     Document Type: Review

References (45)

1. A.F. Shields, J.R. Grierson, B.M. Dohmen, H.J. Machulla, J.C. Stayanoff, J.M. Lawhorn-Crews, and et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 11 1998 Nov 1334 1336
2. L. Kenny, R.C. Coombes, D.M. Vigushin, A. Al-Nahhas, S. Shousha, and E.O. Aboagye Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography Eur J Nucl Med Mol Imaging 34 9 2007 1339 1347
3. V.R. Bollineni, G.S. Kerner, J. Pruim, R.J. Steenbakkers, E.M. Wiegman, M.J. Koole, and et al. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients J Nucl Med 54 8 2013 Aug 1175 1180
4. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 Jan 228 247
5. V.R. Bollineni, S. Collette, and Y. Liu Functional and molecular imaging in cancer drug development Chin Clin Oncol 3 2 2014 Jun 17
6. R. Boellaard, M.J. O'Doherty, W.A. Weber, F.M. Mottaghy, M.N. Lonsdale, S.G. Stroobants, and et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 1 2010 Jan 181 200
7. E.K. Pauwels, M.J. Ribeiro, J.H. Stoot, V.R. McCready, M. Bourguignon, and B. Maziere FDG accumulation and tumor biology Nucl Med Biol 25 4 1998 May 317 322
8. V.R. Bollineni, J. Widder, J. Pruim, J.A. Langendijk, and E.M. Wiegman Residual (1)(8)F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control Int J Radiat Oncol Biol Phys 83 4 2012 Jul 15 e551 e555
9. S.J. Everitt, D.L. Ball, R.J. Hicks, J. Callahan, N. Plumridge, M. Collins, and et al. Differential 18F-FDG and 18F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer J Nucl Med 55 7 2014 Jul 1069 1074
10. K. Herrmann, H.A. Wieder, A.K. Buck, M. Schoffel, B.-J. Krause, F. Fend, and et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma Clin Cancer Res 13 12 2007 3552 3558
11. K. Herrmann, A.K. Buck, T. Schuster, A. Junger, H.A. Wieder, N. Graf, and et al. Predictive value of initial18F-FLT uptake in patients with aggressive non-hodgkin lymphoma receiving R-CHOP treatment J Nucl Med 52 5 2011 690 696
12. K. Herrmann, A.K. Buck, T. Schuster, K. Abbrederis, C. Blumel, I. Santi, and et al. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL Oncotarget 5 12 2014 4050 4059
13. H. Lee, S.-K. Kim, Y.-I. Kim, T.S. Kim, S.H. Kang, W.S. Park, and et al. Early determination of prognosis by interim 3′-deoxy-3′-18FFluorothymidine PET in patients with non-Hodgkin lymphoma J Nucl Med 55 2 2014 216 222
14. M. Scheffler, T. Zander, L. Nogova, C. Kobe, D. Kahraman, M. Dietlein, and et al. Prognostic Impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib PLoS One 8 1 2013
15. D. Kahraman, M. Scheffler, T. Zander, L. Nogova, A.A. Lammertsma, R. Boellaard, and et al. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using18F-FDG and 3′-deoxy-3′-18f-fluorothymidine PET J Nucl Med 52 12 2011 1871 1877
16. H.-J. Sohn, Y.-J. Yang, J.-S. Ryu, J.O. Seung, C.I. Ki, H.M. Dae, and et al. [18F]fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung Clin Cancer Res 14 22 2008 7423 7429
17. T. Zander, M. Scheffler, L. Nogova, C. Kobe, W. Engel-Riedel, M. Hellmich, and et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [18F] fluorothymidine positron emission tomography J Clin Oncol 29 13 2011 1701 1708
18. D. Kahraman, A. Holstein, M. Scheffler, T. Zander, L. Nogova, A.A. Lammertsma, and et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib Clin Nucl Med 37 11 2012 Nov 1058 1064
19. L. Mileshkin, R.J. Hicks, B.G.M. Hughes, P.L.R. Mitchell, V. Charu, B.J. Gitlitz, and et al. Changes in18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib Clin Cancer Res 17 10 2011 3304 3315
20. A. Bhoil, B. Singh, N. Singh, R. Kashyap, A. Watts, S. Sarika, and et al. Can 3′-deoxy-3′-18F-fluorothymidine or 2′-deoxy-2′-18F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results Hell J Nucl Med 17 2 2014 90 96
21. V. Frings, A.A. van der Veldt, R. Boellaard, G.J. Herder, E. Giovannetti, R. Honeywell, and et al. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3′-deoxy-3′-[(1)(8)F]fluorothymidine positron emission tomography PLoS One 8 5 2013 e63705
22. K.B. Contractor, L.M. Kenny, J. Stebbing, L. Rosso, R. Ahmad, J. Jacob, and et al. [18F]-3′deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel Clin Cancer Res 17 24 2011 7664 7672
23. B.S. Pio, C.K. Park, R. Pietras, W.-A. Hsueh, N. Satyamurthy, M.D. Pegram, and et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol Imaging Biol 8 1 2006 36 42
24. W. Chen, S. Delaloye, D.H.S. Silverman, C. Geist, J. Czernin, J. Sayre, and et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 30 2007 4714 4721
25. J. Schwarzenberg, J. Czernin, T.F. Cloughesy, B.M. Ellingson, W.B. Pope, C. Geist, and et al. 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab J Nucl Med 53 1 2012 29 36
26. S.H. Park, J.-S. Ryu, S.-J. Oh, S.-I. Park, Y.H. Kim, H.-Y. Jung, and et al. The feasibility of 18F-fluorothymidine PET for prediction of tumor response after induction chemotherapy followed by chemoradiotherapy with S-1/oxaliplatin in patients with resectable esophageal cancer Nucl Med Mol Imaging 46 1 2012 57 64
27. Y.S. Hong, H.O. Kim, K.-P. Kim, J.-L. Lee, H.J. Kim, S.J. Lee, and et al. 39-deoxy-39-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer J Nucl Med 54 8 2013 1209 1216
28. E.G. Troost, J. Bussink, A.L. Hoffmann, O.C. Boerman, W.J. Oyen, and J.H. Kaanders 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors J Nucl Med 51 6 2010 Jun 866 874
29. Y. Menda, L.L. Boles Ponto, K.J. Dornfeld, T.J. Tewson, G.L. Watkins, M.K. Schultz, and et al. Kinetic analysis of 3′-deoxy-3′-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy J Nucl Med 50 7 2009 Jul 1028 1035
30. T. Saga, M. Koizumi, M. Inubushi, K. Yoshikawa, K. Tanimoto, T. Fukumura, and et al. PET/CT with 3′-deoxy-3′-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy Nucl Med Commun 32 5 2011 May 348 355
31. I. Trigonis, P.K. Koh, B. Taylor, M. Tamal, D. Ryder, M. Earl, and et al. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone Eur J Nucl Med Mol Imaging 41 4 2014 682 693
32. A.I.J. Arens, E.G.C. Troost, B.A.W. Hoeben, W. Grootjans, J.A. Lee, V. Gregoire, and et al. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome Eur J Nucl Med Mol Imaging 41 5 2014 915 924
33. B.A.W. Hoeben, E.G.C. Troost, P.N. Span, C.M.L. van Herpen, J. Bussink, W.J.G. Oyen, and et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome J Nucl Med 54 4 2013 532 540
34. T. Kishino, H. Hoshikawa, Y. Nishiyama, Y. Yamamoto, and N. Mori Usefulness of 3′-deoxy-3′-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer J Nucl Med Off Publ Soc Nucl Med 53 10 2012 1521 1527
35. A. Linecker, C. Kermer, I. Sulzbacher, P. Angelberger, K. Kletter, R. Dudczak, and et al. Uptake of 18F-FLT and 18F-FDG in primary head and neck cancer correlates with survival NuklearMedizin 47 2 2008 80 85
36. H. Chen, Y. Li, H. Wu, L. Sun, Q. Lin, L. Zhao, and et al. 3′-deoxy-3′-[(1)(8)F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [(1)(8)F]-FDG PET/CT Strahlenther Onkol 191 2 2015 Feb 141 152
37. F. Dehdashti, P.W. Grigsby, R.J. Myerson, I. Nalbantoglu, C. Ma, and B.A. Siegel Positron emission tomography with [(18)F]-3′-deoxy-3′fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study Mol Imaging Biol 15 1 2013 Feb 106 113
38. H.A. Wieder, H. Geinitz, R. Rosenberg, F. Lordick, K. Becker, A. Stahl, and et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer Eur J Nucl Med Mol Imaging 34 6 2007 878 883
39. H. Hoshikawa, T. Mori, Y. Yamamoto, T. Kishino, T. Fukumura, Y. Samukawa, and et al. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer Clin Nucl Med 40 6 2015 Jun 464 468
40. H. Hoshikawa, Y. Yamamoto, T. Mori, T. Kishino, T. Fukumura, Y. Samukawa, and et al. Predictive value of SUV-based parameters derived from pre-treatment 18F-FLT PET/CT for short-term outcome with head and neck cancers Ann Nucl Med 28 10 2014 Dec 1020 1026
41. M. Vanderhoek, M.B. Juckett, S.B. Perlman, R.J. Nickles, and R. Jeraj Early assessment of treatment response in patients with AML using [18F]FLT PET imaging Leuk Res 35 3 2011 310 316
42. K. Ott, K. Herrmann, T. Schuster, R. Langer, K. Becker, H.A. Wieder, and et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer Ann Surg Oncol 18 12 2011 Nov 3316 3323
43. A. Challapalli, T. Barwick, R.A. Pearson, S. Merchant, F. Mauri, E.C. Howell, and et al. 3'-Deoxy-3'-(1)(8)F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer Eur J Nucl Med Mol Imaging 42 6 2015 May 831 840
44. M. Inubushi, T. Saga, M. Koizumi, R. Takagi, A. Hasegawa, M. Koto, and et al. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma Ann Nucl Med 27 1 2013 Jan 1 10
45. C. Pfannenberg, P. Aschoff, H. Dittmann, F. Mayer, G. Reischl, W.C. Von, and et al. PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med 51 6 2010 Jun 845 853